Versaterm Welcomes Reuben Ramirez as Executive Partner Success Manager for Its Expanded Health and Wellness Program
January 23, 2025 09:00 ET
|
Versaterm
OTTAWA, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Versaterm, a global leader in public safety solutions, welcomes Reuben Ramirez, former Assistant Chief of Police for the Dallas Police Department (Dallas...
Schizophrenia Drugs Market Size is Projected to Reach USD 12.33 Billion by 2033, Growing at a CAGR of 5.10%: Straits Research
January 22, 2025 10:12 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pharmaceutical interventions for schizophrenia are designed to effectively treat and mitigate the symptoms associated with schizophrenia, a...
Marking Bell’s Let’s Talk Day 2025, Environics Analytics Announces Its Partnership with Kids Help Phone in Support of Youth Mental Health
January 22, 2025 10:00 ET
|
Environics Analytics
Environics Analytics announces partnership in support of youth mental health.
Kids Help Phone Launches acceleratorKHP Globally during Davos 2025
January 22, 2025 08:00 ET
|
Kids Help Phone
Toronto, Ontario, Canada, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Following a successful Canadian launch at the Elevate Festival in October, Kids Help Phone (KHP) debuts acceleratorKHP during the World...
Problem Debt Significantly Affecting Mental Health of British Columbians, Consumers Waiting Longer to Seek Help – 12th Annual BC Consumer Debt Study
January 20, 2025 08:00 ET
|
Sands & Associates
Latest BC Consumer Debt Study shows debt is having serious impacts on consumers’ mental health and individuals are waiting longer than ever to seek help.
Digbi Health Expands its Multi-Condition Care Platform to Enhance Efficacy and Adherence to GLP-1 Drugs
January 17, 2025 05:21 ET
|
Digbi Health
PALO ALTO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Digbi Health, a pioneer in Precision Biology, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its...
Boehringer provides update on iclepertin Phase III program in schizophrenia
January 16, 2025 10:05 ET
|
Boehringer Ingelheim Limited
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were...
The Burns Way Launches with Over 50 Volunteer Veteran Peers
January 15, 2025 04:00 ET
|
The Burns Way
The Burns Way, anonymous peer support program, is now available to Canadian Veterans looking for judgement-free connections with trained Veteran peers.
WGU Labs Invests in Genius Academy to Transform Mental Health Education with Innovative AI-Driven Simulations
January 14, 2025 09:00 ET
|
Western Governors University
SALT LAKE CITY, Jan. 14, 2025 (GLOBE NEWSWIRE) -- WGU Labs, the research, development, and investment arm of Western Governors University, has announced an investment and partnership with Genius...
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
January 10, 2025 07:00 ET
|
GH Research PLC
Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8Primary endpoint...